WCLC 2025 - Posters & ePosters-P3.12.56 Medication Adherence to Osimertinib in Patients Diagnosed With Metastatic Non Small Cell Lung Cancer

Pdf Summary

This retrospective chart review study assessed medication adherence (MA) to osimertinib among 38 patients with EGFR-mutated metastatic non-small cell lung cancer (NSCLC) treated at a large academic community cancer center between 2018 and 2023. Osimertinib is an oral targeted therapy commonly used in this patient population. <br /><br />Adherence was defined as having a proportion of days covered (PDC) of 90% or higher during the first six months of therapy. The cohort had a mean age of 63.2 years, was predominantly female (71%) and ethnically diverse. Patients filled prescriptions at either internal (34%) or external (66%) pharmacies.<br /><br />Results showed a high overall mean PDC of 96.19%, indicating excellent adherence. Internal pharmacy users had a slightly higher mean PDC (96.85%) than external pharmacy users (95.83%), but the difference was not statistically significant (p=0.53). This adherence rate surpasses previously reported rates for lung cancer oral therapies, which range from approximately 65% to 83%. The study suggests that the Memorial Healthcare System’s coordinated medication management efforts contribute to consistently high adherence regardless of pharmacy setting.<br /><br />The secondary objective focused on whether pharmacy type affected the timeliness of prescription refills; however, specific details on this were not provided in the summary.<br /><br />In conclusion, patients with metastatic EGFR-mutated NSCLC treated with osimertinib at this center demonstrated notably higher medication adherence than previously reported in literature. The findings underscore the importance of a coordinated, multidisciplinary approach to managing oral cancer therapies to optimize treatment outcomes. High adherence to osimertinib supports its use as an effective oral oncolytic in this population.

Asset Subtitle

Daniel Rosas

Meta Tag

Speaker Daniel Rosas

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

osimertinib

medication adherence

EGFR-mutated NSCLC

metastatic non-small cell lung cancer

proportion of days covered

oral targeted therapy

pharmacy type

Memorial Healthcare System

coordinated medication management

oral cancer therapies